Hikma Pharmaceuticals PLC
LSE:HIK
Hikma Pharmaceuticals PLC
LSE:HIK
Price:
1 994 GBX
0.66%
Market Closed
Updated:
May 11, 2024
Hikma Pharmaceuticals PLC
Cash from Operating Activities
|
Hikma Pharmaceuticals PLC
Cash from Operating Activities Peer Comparison
Comparables:
GSK
AZN
VRNA
INDV
DPH
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Operating Activities
$608m
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Operating Activities
£7.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Operating Activities
$9.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
33%
|
CAGR 10-Years
4%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Operating Activities
-$50.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Operating Activities
-$334m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Operating Activities
£63.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
See Also
What is Hikma Pharmaceuticals PLC's Cash from Operating Activities?
Cash from Operating Activities
608m
USD
608m
USD
Based on the financial report for Dec 31, 2023, Hikma Pharmaceuticals PLC's Cash from Operating Activities amounts to 608m USD.
What is Hikma Pharmaceuticals PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
6%
6%
Over the last year, the Cash from Operating Activities growth was 15%. The average annual Cash from Operating Activities growth rates for Hikma Pharmaceuticals PLC have been 9% over the past three years , 7% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
